COLA: Updates on Food Allergy Research

Price: $25 members, $35 non-members
Session recorded on October 26, 2018
Speaker:  Edwin Kim, MD
Viewers can earn credit by completing the posttest questions.

Educate the learner on prior food immunotherapy studies so that the learner can best interpret and put into perspective new data on food allergy treatments being submitted to the FDA.  No treatments are available for food allergy but multiple investigational products are in development. Multiple small and heterogeneous studies of OIT, SLIT and EPIT have been published or reported which are the basis of the therapies being presented to the FDA. In order to best evaluate these new therapies, a thorough understanding of these previous studies including efficacy data as well as pros and cons of therapy are needed.
 

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Target Audience

Practicing allergists and immunologists
Fellows-in-training

 

Learning Objectives

After viewing the video recording, learners should be able to:

•    Food allergy prevalence
•    Review the current standard of care
•    Provide an overview of the concept of food immunotherapy
•    Summarize key findings from clinical trials of food immunotherapy including OIT, SLIT, EPIT and SCIT
•    Review the potential benefits as well as the shortcomings of the different modalities

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.
Jay Portnoy, MD, Planner
Speaker, honorarium: Thermofisher, Boehringer Ingelheim
Edwin Kim, MD, Speaker
Consultant, honorarium: Aimmune
Advisory board member, Consultant: DBV Technologies

The following have no financial relationships to disclose:
Paul Dowling, MD, Planner
 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
10/26/2018
Course expires: 
12/31/2019
Cost:
$35.00
Rating: 
0

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
10/26/2018
Course expires: 
12/31/2019

Price

Cost:
$35.00
Please login or create an account to take this course.